205 related articles for article (PubMed ID: 25081843)
1. Screening prior to biological therapy in Crohn's disease: adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study.
van der Have M; Belderbos TD; Fidder HH; Leenders M; Dijkstra G; Peters CP; Eshuis EJ; Ponsioen CY; Siersema PD; van Oijen MG; Oldenburg B;
Dig Liver Dis; 2014 Oct; 46(10):881-6. PubMed ID: 25081843
[TBL] [Abstract][Full Text] [Related]
2. Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment.
Carpio D; Jauregui-Amezaga A; de Francisco R; de Castro L; Barreiro-de Acosta M; Mendoza JL; Mañosa M; Ollero V; Castro B; González-Conde B; Hervías D; Sierra Ausin M; Sancho Del Val L; Botella-Mateu B; Martínez-Cadilla J; Calvo M; Chaparro M; Ginard D; Guerra I; Maroto N; Calvet X; Fernández-Salgado E; Gordillo J; Rojas Feria M;
J Crohns Colitis; 2016 Oct; 10(10):1186-93. PubMed ID: 26802085
[TBL] [Abstract][Full Text] [Related]
3. Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.
Abitbol Y; Laharie D; Cosnes J; Allez M; Nancey S; Amiot A; Aubourg A; Fumery M; Altwegg R; Michetti P; Chanteloup E; Seksik P; Baudry C; Flamant M; Bouguen G; Stefanescu C; Bourrier A; Bommelaer G; Dib N; Bigard MA; Viennot S; Hébuterne X; Gornet JM; Marteau P; Bouhnik Y; Abitbol V; Nahon S;
J Crohns Colitis; 2016 Oct; 10(10):1179-85. PubMed ID: 27402916
[TBL] [Abstract][Full Text] [Related]
4. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study.
Bermejo F; Algaba A; Chaparro M; Taxonera C; Garrido E; García-Arata I; Guerra I; Gisbert JP; Olivares D; de-la-Poza G; López-Sanromán A
Dig Liver Dis; 2013 Sep; 45(9):733-7. PubMed ID: 23587496
[TBL] [Abstract][Full Text] [Related]
5. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
[TBL] [Abstract][Full Text] [Related]
6. Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on Crohn's disease: a real-life survey in Spain.
Hinojosa J; Gisbert JP; Gomollón F; López San Román A
J Crohns Colitis; 2012 Aug; 6(7):763-70. PubMed ID: 22398092
[TBL] [Abstract][Full Text] [Related]
7. Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease.
van der Have M; Oldenburg B; Fidder HH; Belderbos TD; Siersema PD; van Oijen MG
Dig Dis Sci; 2014 Mar; 59(3):554-63. PubMed ID: 23949640
[TBL] [Abstract][Full Text] [Related]
8. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
[TBL] [Abstract][Full Text] [Related]
9. A case of opportunistic skin infection with Mycobacterium marinum during adalimumab treatment in a patient with Crohn's disease.
Kump PK; Högenauer C; Wenzl HH; Petritsch W
J Crohns Colitis; 2013 Feb; 7(1):e15-8. PubMed ID: 22770648
[TBL] [Abstract][Full Text] [Related]
10. Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.
Sauzullo I; Mengoni F; Marocco R; Potenza C; Skroza N; Tieghi T; Lichtner M; Vullo V; Mastroianni CM
Br J Dermatol; 2013 Nov; 169(5):1133-40. PubMed ID: 23909256
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
Riis A; Martinsen TC; Waldum HL; Fossmark R
Scand J Gastroenterol; 2012 Jun; 47(6):649-57. PubMed ID: 22472026
[TBL] [Abstract][Full Text] [Related]
12. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment.
Nordgaard-Lassen I; Dahlerup JF; Belard E; Gerstoft J; Kjeldsen J; Kragballe K; Ravn P; Sørensen IJ; Theede K; Tjellesen L;
Dan Med J; 2012 Jul; 59(7):C4480. PubMed ID: 22759856
[TBL] [Abstract][Full Text] [Related]
13. [Immune reconstitution syndrome in a case of disseminated tuberculosis after withdrawal of treatment with adalimumab].
Jorge-Ripper C; Pelazas R; González-Pérez JM; Santolaria F
Rev Clin Esp; 2012 Apr; 212(4):219-21. PubMed ID: 22386757
[No Abstract] [Full Text] [Related]
14. Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease.
Walsh AJ; Weltman M; Burger D; Vivekanandarajah S; Connor S; Howlett M; Radford-Smith G; Selby W; Veillard AS; Grimm MC; Travis SP; Lawrance IC
J Crohns Colitis; 2013 Nov; 7(10):e449-56. PubMed ID: 23601754
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
[TBL] [Abstract][Full Text] [Related]
16. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
[TBL] [Abstract][Full Text] [Related]
18. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
[TBL] [Abstract][Full Text] [Related]
19. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?
Millonig G; Kern M; Ludwiczek O; Nachbaur K; Vogel W
World J Gastroenterol; 2006 Feb; 12(6):974-6. PubMed ID: 16521231
[TBL] [Abstract][Full Text] [Related]
20. [Development of cervical tuberculous lymphadenitis in a patient with Crohn's disease receiving infliximab despite of chemoprophylaxis with isoniazid].
Ikeue T; Nakagawa A; Furuta K; Morita K; Sugita T; Nishiyama H
Kekkaku; 2011 Nov; 86(11):879-82. PubMed ID: 22250467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
